MacroGenics, Inc.

Intellectual property agreement signed for anti-CD3

Published in Elder Law Weekly, August 17th, 2005

MacroGenics, Inc., announced the signing of an agreement with Tolerance Therapeutics, Inc., in which MacroGenics will acquire the intellectual property, materials, and know-how related to a promising anti-CD3 monoclonal antibody for the treatment of type 1, or juvenile, diabetes and other autoimmune diseases.

A key monoclonal antibody clinically shown to play an important role in fighting juvenile diabetes, anti-CD3 targets an antigen expressed on T lymphocytes, the cells of the immune system that are responsible for the destruction of islet cells of the pancreas and could slow the progression of the disease in children and adolescents.

A phase I...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2005-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry